Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01241513 · ClinicalTrials.gov registry record · Phase 4
Induced Changes in Ventilatory Responsiveness and Altitude Exposure
A Phase 4 study, sponsored by United States Army Research Institute of Environmental Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT01241513 is a Phase 4 study that was terminated before completion, run by United States Army Research Institute of Environmental Medicine. The registered enrollment target is 21 participants.
The verdict
NCT01241513, a Phase 4 study, was terminated before completion, sponsored by United States Army Research Institute of Environmental Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine if a drug (acetyl-cysteine or ACCY) can increase the amount of oxygen in your body at a high altitude of 11,500 feet. ACCY is approved by the Food and Drug Administration (FDA) as a treatment or antidote for Tylenol overdoses. Other forms of ACCY are also sold over-the-counter as nutritional supplements. In this study, the FDA-approved form of ACCY will be used "off-label" (meaning in a way not approved by the FDA). This study is being conducted by researchers from the United States Army Research Institute of Environmental Medicine (USARIEM). The study will take place in the Altitude Chamber located in the basement of USARIEM. A total of approximately 30 volunteers (men and women, military and civilians) will take part in the study. They can expect to be in the study for a minimum of a few hours each day for two weeks. The investigators hypothesize that ACCY will improve ventilation and oxygenation while at altitude.
Interventions
- DRUG Placebo
- DRUG NAC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-11-01 |
| Est. Completion | 2013-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01241513
The ClinicalTrials.gov registry entry for NCT01241513 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United States Army Research Institute of Environmental Medicine, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01241513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01241513 about?
NCT01241513 is a clinical study titled "Induced Changes in Ventilatory Responsiveness and Altitude Exposure". The main purpose of this study is to determine if a drug (acetyl-cysteine or ACCY) can increase the amount of oxygen in your body at a high altitude of 11,500 feet. ACCY is approved by the Food and Drug Administration (FDA) as a treatment or antidote for Tylenol overdoses. Other forms of ACCY are al...
What is the current status of trial NCT01241513?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2010-11-01. Estimated completion is 2013-02-28.
What interventions are being tested in trial NCT01241513?
The interventions under investigation include: Placebo (DRUG), NAC (DRUG).
Who is sponsoring clinical trial NCT01241513?
This trial is sponsored by United States Army Research Institute of Environmental Medicine, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.